Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...

Immutep (IMMP) announces positive clinical results from Cohort B of the TACTI-003 Phase IIb trial. This study evaluates eftilagimod alpha in ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing ...

Immutep (ASX:IMM) has announced promising new data from its Phase IIb TACTI-003 trial, presented at the ESMO Immuno-Oncology Congress 2024.

Immutep (ASX:IMM) has announced the initiation of its TACTI-004 Phase III clinical trial, which aims to evaluate the efficacy ...

Immutep Limited (NASDAQ:IMMP) recently released positive results from its phase 1 INSIGHT-003 study, which used its drug efti [eftilagimod alpha] in combination with KEYTRUDA and chemotherapy for ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease ...

Baird analyst Joel Beatty raised the firm’s price target on Immutep (IMMP) to $7 from $6 and keeps an Outperform rating on the shares. The firm raised its target after the company announced ...

Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The biotech ...

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday. The post ASX 300 healthcare stock lifts off on promising new results appeared first on The Motley Fool Australia.